image
Mobile_image
eyebrow
For adults with classical Hodgkin lymphoma after a stem cell transplant
headline

How may I benefit from ADCETRIS?

section-tab-header
true
section-tab-text-wrap
true
collection-color-theme
color-theme-4-core-tinted-on-white
headline

AETHERA study design

content

AETHERA was a large clinical study of 329 people that compared the effectiveness and safety of ADCETRIS with placebo in patients with classical Hodgkin lymphoma that has a high risk of coming back or getting worse after a stem cell transplant.

  • 165 people were assigned to receive ADCETRIS every 3 weeks for up to 16 cycles
  • 164 people were assigned to receive placebo every 3 weeks for up to 16 cycles


High-risk classical Hodgkin lymphoma was defined in the study as when the first therapy does not work and the cancer does not respond to treatment, when disease returns within 12 months of the first treatment, or when disease returns more than 12 months after the first treatment, and there are signs of lymphoma in areas or organs outside the lymph nodes.

Researchers reviewed the progression-free survival results (primary endpoint) and the median time to cancer progression or death at approximately 2 years.

headline

Progression-free survival results

subheadline

More people treated with ADCETRIS did not experience cancer progression or death compared to placebo.

Image
Mobile_image
content
Nearly 2 years after treatment, 36% of the 165 patients treated with ADCETRIS experienced cancer progression or death compared to 46% of the 164 patients who received placebo.
headline

Median time to cancer progression or death

content
After enrolling in the study, people treated with ADCETRIS experienced significantly more time without cancer progression or death compared to placebo.
image
Mobile_image
section-tabbed-title
Study Results
section-tab-header-alignment
center
collection-container
content-container
collection-container-variant
grid
collection-item-type
core-content, core-text
section-tabbed-title
Side Effects
section-tab-header-alignment
center
headline

What safety information should I know about ADCETRIS?

icon
headline

The most important serious safety information

content
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.

Do not take ADCETRIS with bleomycin because of possible serious side effects to the lungs. These are not the only side effects of ADCETRIS. Always tell your doctor about any side effects you experience.
icon
headline

Most common side effects while taking ADCETRIS

content
In people treated with ADCETRIS alone, the most common side effects that occurred in ≥20% of study patients were significantly low number of white blood cells (78%), nerve damage (peripheral sensory neuropathy; PN) (56%), low platelet count (41%), low red blood cell count (27%), upper respiratory tract infection (26%), feeling tired (24%), weakness in the hands or feet (peripheral motor neuropathy) (23%), nausea (22%), cough (21%), and diarrhea (20%).

The most common serious side effects that occurred in study patients were pneumonia (4%), fever (4%), vomiting (3%), nausea (2%), liver damage (2%), and PN (2%).

For more information on side effects, please see the Important Safety Information at the bottom of this page and read the Important Facts about ADCETRIS, including BOXED WARNING.
headline

Tell your doctor about any side effect concerns you have

content

Don’t stop, change, or delay your ADCETRIS treatment unless directed by your doctor. Your doctor may take additional steps to help manage side effects, including:

  • Reducing your ADCETRIS dosage, or delaying your next dose, until symptoms improve
  • Stopping ADCETRIS completely if side effects are severe or do not improve


For more information about understanding side effects, download a copy of the ADCETRIS side effects guide

headline

Learn more about what you can expect before starting ADCETRIS treatment.

content
buttons
Find out how ADCETRIS is given
headline

Glossary

content

Median: The middle number in a list of numbers.

Placebo: An inactive substance that does not contain medication. In clinical studies, it looks the same and is given the same way as the medication being tested.

Progression-free survival: The length of time during and after treatment that a person lives without their cancer getting worse.

Stem cell transplant: A procedure in which a patient receives healthy stem cells (blood-forming cells) to replace their own stem cells that have been destroyed by certain cancer treatments.